IMPORTANT CLINICAL PHARMACOLOGIC CONSIDERATIONS IN THE USE OF METHADONE IN CANCER-PATIENTS

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (3) , 457-459
Abstract
The manufacturer''s recommended dose of methadone, i.e., 2.5-10 mg every 3-4 h, is excessive. Methadone has an average primary-phase half-life of 14.3 h and a slower secondary-phase half-life averaging 54.8 h. Administering the recommended dose of methadone and escalating doses within 2-3 days may lead to very high plasma levels of the drug. In addition, factors such as drug-drug interaction and/or hepatic and renal dysfunction may affect methadone metabolism and result in its accumulation. Methadone is an effective analgesic whose pharmacokinetics must be appreciated in order for it to be used safely and effectively. Three cases of methadone overdose are presented.